

Sam M Hanash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4411526/publications.pdf>

Version: 2024-02-01

100
papers

11,494
citations

38742

50
h-index

34986

98
g-index

107
all docs

107
docs citations

107
times ranked

18087
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930. | 12.6 | 1,872 |
| 2 | Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008, 14, 822-827. | 30.7 | 1,015 |
| 3 | Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 304-313. | 3.8 | 813 |
| 4 | JAK/STAT3-Regulated Fatty Acid β -Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. <i>Cell Metabolism</i> , 2018, 27, 136-150.e5. | 16.2 | 519 |
| 5 | Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207. | 7.1 | 438 |
| 6 | Stability of the hybrid epithelial/mesenchymal phenotype. <i>Oncotarget</i> , 2016, 7, 27067-27084. | 1.8 | 367 |
| 7 | The Emerging Role of B Cells in Tumor Immunity. <i>Cancer Research</i> , 2016, 76, 5597-5601. | 0.9 | 278 |
| 8 | Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 142-150. | 27.6 | 277 |
| 9 | Protein profiles associated with survival in lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13537-13542. | 7.1 | 262 |
| 10 | Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. , 2019, 194, 161-184. | | 244 |
| 11 | Computational Proteomics Analysis System (CPAS): An Extensible, Open-Source Analytic System for Evaluating and Publishing Proteomic Data and High Throughput Biological Experiments. <i>Journal of Proteome Research</i> , 2006, 5, 112-121. | 3.7 | 204 |
| 12 | Organ-Specific Molecular Classification of Primary Lung, Colon, and Ovarian Adenocarcinomas Using Gene Expression Profiles. <i>American Journal of Pathology</i> , 2001, 159, 1231-1238. | 3.8 | 180 |
| 13 | Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival. <i>Cancer Research</i> , 2015, 75, 1789-1800. | 0.9 | 179 |
| 14 | Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera. <i>Journal of Clinical Oncology</i> , 2008, 26, 5060-5066. | 1.6 | 178 |
| 15 | Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1555-64. | 7.1 | 174 |
| 16 | Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models. <i>Cancer Cell</i> , 2011, 20, 289-299. | 16.8 | 158 |
| 17 | A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 197-203. | 3.8 | 151 |
| 18 | Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , 2021, 27, 141-151. | 30.7 | 134 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Integrated global profiling of cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 638-644. | 28.4 | 132 |
| 20 | Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414. | 27.8 | 129 |
| 21 | Development of Natural Protein Microarrays for Diagnosing Cancer Based on an Antibody Response to Tumor Antigens. <i>Journal of Proteome Research</i> , 2004, 3, 261-267. | 3.7 | 127 |
| 22 | Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitinC-terminal hydrolase L3. <i>Proteomics</i> , 2003, 3, 2108-2115. | 2.2 | 126 |
| 23 | Targets of the Tumor Suppressor <i>miR-200</i> in Regulation of the Epithelial-Mesenchymal Transition in Cancer. <i>Cancer Research</i> , 2011, 71, 7670-7682. | 0.9 | 126 |
| 24 | Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , 2019, 10, 254. | 12.8 | 120 |
| 25 | An Autoantibody-Mediated Immune Response to Calreticulin Isoforms in Pancreatic Cancer. <i>Cancer Research</i> , 2004, 64, 5504-5510. | 0.9 | 119 |
| 26 | Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266. | 6.3 | 116 |
| 27 | Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. <i>JAMA Oncology</i> , 2018, 4, e182078. | 7.1 | 109 |
| 28 | HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451. | 12.8 | 107 |
| 29 | Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170512. | 3.4 | 104 |
| 30 | Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. <i>Gut</i> , 2020, 69, 18-31. | 12.1 | 94 |
| 31 | In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7301-E7310. | 7.1 | 88 |
| 32 | Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. <i>Proteomics</i> , 2003, 3, 2200-2207. | 2.2 | 85 |
| 33 | MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. <i>Cancer Research</i> , 2017, 77, 4414-4425. | 0.9 | 85 |
| 34 | Harnessing immunity for cancer marker discovery. <i>Nature Biotechnology</i> , 2003, 21, 37-38. | 17.5 | 84 |
| 35 | Identification of 14-3-3 η as an Antigen that Induces a Humoral Response in Lung Cancer. <i>Cancer Research</i> , 2007, 67, 12000-12006. | 0.9 | 79 |
| 36 | A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 372-379. | 6.3 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , 2021, 160, 1373-1383.e6. | 1.3 | 77 |
| 38 | Proinflammatory Surfactant Protein B As a Biomarker for Lung Cancer Prediction. <i>Journal of Clinical Oncology</i> , 2013, 31, 4536-4543. | 1.6 | 73 |
| 39 | Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 6.3 | 72 |
| 40 | Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer. <i>APL Bioengineering</i> , 2018, 2, 031908. | 6.2 | 71 |
| 41 | Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. <i>Metabolites</i> , 2015, 5, 192-210. | 2.9 | 69 |
| 42 | Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw231. | 6.3 | 69 |
| 43 | Distinguishing mechanisms underlying EMT tristability. <i>Cancer Convergence</i> , 2017, 1, 2. | 8.0 | 69 |
| 44 | Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based Framework. <i>American Journal of Pathology</i> , 2003, 163, 1985-1995. | 3.8 | 64 |
| 45 | Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?. <i>Molecular Oncology</i> , 2017, 11, 739-754. | 4.6 | 64 |
| 46 | Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 95466-95480. | 1.8 | 60 |
| 47 | Integral Protein Microarrays for the Identification of Lung Cancer Antigens in Sera That Induce a Humoral Immune Response. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 268-281. | 3.8 | 58 |
| 48 | Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space. <i>Journal of Biological Chemistry</i> , 2016, 291, 25799-25808. | 3.4 | 58 |
| 49 | Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera. <i>Cancer Prevention Research</i> , 2012, 5, 1036-1043. | 1.5 | 57 |
| 50 | Autoantibody Signatures Involving Glycolysis and Spliceosome Proteins Precede a Diagnosis of Breast Cancer among Postmenopausal Women. <i>Cancer Research</i> , 2013, 73, 1502-1513. | 0.9 | 57 |
| 51 | Integrated Proteomic Analysis of Human Cancer Cells and Plasma from Tumor Bearing Mice for Ovarian Cancer Biomarker Discovery. <i>PLoS ONE</i> , 2009, 4, e7916. | 2.5 | 53 |
| 52 | Unleashing the Power of Proteomics to Develop Blood-Based Cancer Markers. <i>Clinical Chemistry</i> , 2013, 59, 119-126. | 3.2 | 52 |
| 53 | Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. <i>Nature Communications</i> , 2020, 11, 4279. | 12.8 | 52 |
| 54 | Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers. <i>Disease Markers</i> , 2004, 20, 149-153. | 1.3 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | In-Depth Proteomics to Define the Cell Surface and Secretome of Ovarian Cancer Cells and Processes of Protein Shedding: Figure 1.. Cancer Research, 2009, 69, 728-730. | 0.9 | 48 |
| 56 | Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. Journal of Clinical Oncology, 2022, 40, 876-883. | 1.6 | 43 |
| 57 | Identification of Defensin $\alpha 6$ as a Potential Biomarker in Colon Adenocarcinoma. Journal of Biological Chemistry, 2005, 280, 8260-8265. | 3.4 | 42 |
| 58 | Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Medicine, 2009, 1, 47. | 8.2 | 41 |
| 59 | Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 607-616. | 6.3 | 40 |
| 60 | Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 407-413. | 2.7 | 37 |
| 61 | Identification of Tumor-Associated Antigens Using Proteomics. Technology in Cancer Research and Treatment, 2002, 1, 257-262. | 1.9 | 35 |
| 62 | Testing the gene expression classification of the EMT spectrum. Physical Biology, 2019, 16, 025002. | 1.8 | 35 |
| 63 | Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. Cells, 2020, 9, 1518. | 4.1 | 35 |
| 64 | An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. Cancer Research, 2015, 75, 3246-3254. | 0.9 | 33 |
| 65 | Blood based biomarkers beyond genomics for lung cancer screening. Translational Lung Cancer Research, 2018, 7, 327-335. | 2.8 | 33 |
| 66 | Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor. Chemical Science, 2019, 10, 8428-8437. | 7.4 | 33 |
| 67 | Switching Roles of TGF- $\beta 2$ in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. Journal of Clinical Medicine, 2016, 5, 109. | 2.4 | 30 |
| 68 | Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer. Cancer Research, 2012, 72, 1935-1942. | 0.9 | 27 |
| 69 | Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers. Genome Medicine, 2014, 6, 12. | 8.2 | 26 |
| 70 | MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. Cancer Prevention Research, 2015, 8, 1112-1119. | 1.5 | 25 |
| 71 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329. | 3.4 | 25 |
| 72 | Development of autoantibody signatures for common cancers. Seminars in Immunology, 2020, 47, 101388. | 5.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Circulating Pro-Surfactant Protein B as a Risk Biomarker for Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1756-1761. | 2.5 | 24 |
| 74 | Protein citrullination as a source of cancer neoantigens. , 2021, 9, e002549. | | 24 |
| 75 | Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. <i>Gut</i> , 2021, 70, 2055-2065. | 12.1 | 24 |
| 76 | Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. <i>Journal of Thoracic Oncology</i> , 2021, 16, 228-236. | 1.1 | 22 |
| 77 | Identification of a Specific Vimentin isoform that Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , 2006, 1, 117727190600100. | 2.5 | 21 |
| 78 | Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. <i>Proteomics</i> , 2014, 14, 2750-2759. | 2.2 | 20 |
| 79 | Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. <i>Cancers</i> , 2020, 12, 1147. | 3.7 | 20 |
| 80 | Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. <i>PLoS ONE</i> , 2016, 11, e0152300. | 2.5 | 20 |
| 81 | A plasma protein derived TGF β 2 signature is a prognostic indicator in triple negative breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 10. | 5.4 | 18 |
| 82 | Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1549-1557. | 0.9 | 18 |
| 83 | SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. <i>Journal of the National Cancer Institute</i> , 2022, 114, 290-301. | 6.3 | 18 |
| 84 | Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , 2006, 1, 175-183. | 2.5 | 18 |
| 85 | Increased Throughput and Reduced Carryover of Mass Spectrometry-Based Proteomics Using a High-Efficiency Nonsplit Nanoflow Parallel Dual-Column Capillary HPLC System. <i>Journal of Proteome Research</i> , 2008, 7, 2743-2755. | 3.7 | 17 |
| 86 | Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2543. | 3.7 | 16 |
| 87 | A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. <i>Cancers</i> , 2021, 13, 913. | 3.7 | 15 |
| 88 | CES2 sustains HNF4 α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. <i>Molecular Metabolism</i> , 2022, 56, 101426. | 6.5 | 14 |
| 89 | Mass spectrometry based proteomics for absolute quantification of proteins from tumor cells. <i>Methods</i> , 2015, 81, 34-40. | 3.8 | 13 |
| 90 | Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. <i>BJU International</i> , 2018, 121, 69-76. | 2.5 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. <i>Cancers</i> , 2020, 12, 485. | 3.7 | 9 |
| 92 | CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. <i>JCO Precision Oncology</i> , 2020, 4, 426-436. | 3.0 | 9 |
| 93 | The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves. <i>Statistics in Medicine</i> , 2021, 40, 1767-1789. | 1.6 | 9 |
| 94 | A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4969-e4980. | 3.6 | 9 |
| 95 | Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. <i>Cancers</i> , 2020, 12, 746. | 3.7 | 6 |
| 96 | Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 50. | 5.2 | 6 |
| 97 | Deciphering the complexity of the cancer proteome for diagnostic applications. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 399-405. | 3.1 | 5 |
| 98 | Proteomic Profiling of the Tumor Microenvironment. <i>Methods in Molecular Biology</i> , 2022, 2435, 157-167. | 0.9 | 2 |
| 99 | The Wide World of Molecular Profiling for Tumor Classification. <i>Clinical Chemistry</i> , 2018, 64, 743-744. | 3.2 | 1 |
| 100 | N1,N12-Diacetylspermine as a Blood Based Lung Cancer Biomarker. <i>Biochemistry and Analytical Biochemistry: Current Research</i> , 2016, 5, . | 0.4 | 0 |